Head-to-head evidence
albuterol / budesonide vs indacaterol maleate / mometasone furoate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
indacaterol maleate / mometasone furoate
Developed by Novartis
NCT00557440 · Phase 2 · completed
The study was randomized and quadruple-blind, used both placebo and active control, and measured the clinically relevant lung-function endpoint FEV1. Although the primary comparison favored indacaterol/mometasone over placebo and was statistically significant, the small sample of 37 participants limits the strength of the evidence.
Next expected readout: February 2028 · NCT05562466 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · indacaterol maleate / mometasone furoate's landscape